ArticleJournal of neuroinflammation2026
Ginsenoside Rg2 attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3-mediated pyroptosis.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIntracerebral hemorrhage (ICH) is a devastating stroke subtype without effective therapy. Neuroinflammation, particularly driven by NLRP3 inflammasome–mediated pyroptosis, is a key contributor to secondary brain injury (SBI). Ginsenoside Rg2 (Rg2), a natural saponin with anti-inflammatory activity, has been reported to inhibit NLRP3, but its efficacy and mechanisms in ICH remain unclear.
methodsIn a collagenase-induced ICH mouse model, we evaluated the effects of Rg2 on neurological function, cerebral blood flow, hematoma expansion, neuronal injury, and inflammation. Mechanistic studies included RNA sequencing, western blotting, immunostaining, co-treatment with MCC950, and microglial depletion with PLX3397. Serum NLRP3 levels were analyzed in patients with ICH.
resultsRg2 improved acute and long-term neurological and cognitive recovery, restored cerebral blood flow, reduced hematoma expansion, and alleviated neuronal damage. It suppressed central and peripheral inflammation, limiting microglial and astrocytic overactivation. Mechanistically, Rg2 directly targeted NLRP3 to selectively inhibit NLRP3 inflammasome activation and pyroptosis while sparing NLRC4 and AIM2. Partial microglial depletion abolished its benefit, and MCC950 co-treatment produced no additive effect. Serum NLRP3 levels correlated with ICH severity and were reduced by Rg2. Long-term treatment showed no organ toxicity.
conclusionsRg2 confers robust neuroprotection against ICH by selectively targeting NLRP3-mediated pyroptosis, offering both acute and long-term benefits. These findings support Rg2 as a promising candidate for ICH and potentially for other NLRP3-related neuroinflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.